Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer-Reference-Cited by-同舟云学术

Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer

Published:2020-09-10 Issue:22 Volume:126 Page:4948-4956
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Duska Linda R.¹^ORCID,Scalici Jennifer M.²,Temkin Sarah M.³^ORCID,Schwarz Julie K.⁴,Crane Erin K.⁵,Moxley Katherine M.⁶,Hamilton Chad A.⁷,Wethington Stephanie L.⁸,Petroni Gina R.⁹,Varhegyi Nikole E.⁹,Clift Sheena H.¹,Bullock Timothy N. J.¹⁰,Showalter Timothy N.¹¹

Affiliation:

1. Division of Gynecologic Oncology Department of Obstetrics and Gynecology University of Virginia School of Medicine Charlottesville Virginia

2. Mitchell Cancer InstituteUSA Health Mobile Alabama

3. Anne Arundel Medical Center Annapolis Maryland

4. Department of Radiation Oncology Washington University School of Medicine Saint Louis Missouri

5. Division of Gynecologic Oncology Levine Cancer Institute Charlotte North Carolina

6. Stephenson Cancer Center University of Oklahoma Sciences Center Oklahoma City Oklahoma

7. Inova Schar Cancer Institute Fairfax Virginia

8. Division of Gynecologic Oncology Department of Gynecology and Obstetrics Johns Hopkins School of Medicine Baltimore Maryland

9. Public Health Sciences University of Virginia School of Medicine Charlottesville Virginia

10. Department of Pathology University of Virginia School of Medicine Charlottesville Virginia

11. Department of Radiation Oncology University of Virginia School of Medicine Charlottesville Virginia

Funder

Merck

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33136

Reference18 articles.

1. Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials

2. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

3. Concurrent Radiation and Immunotherapy

4. Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma

5. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bridging the Gap: Immune Checkpoint Inhibitor as an Option in the Management of Advanced and Recurrent Cervical Cancer in Sub-Saharan Africa;Cureus;2024-09-10

2. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial;The Lancet;2024-09

3. Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer;Journal of Obstetrics and Gynaecology;2024-08-16

4. New Frontiers in Locally Advanced Cervical Cancer Treatment;Journal of Clinical Medicine;2024-07-30

5. Clinical Outcomes and Molecular Predictors of Pembrolizumab (Keytruda) as a PD-1 Immune Checkpoint Inhibitor in Advanced and Metastatic Cervical Cancer: A Systematic Review and Meta-Analysis;Biomedicines;2024-05-16